Truist Financial Corp Has $6.30 Million Stock Holdings in Labcorp Holdings Inc. $LH

Truist Financial Corp raised its position in Labcorp Holdings Inc. (NYSE:LH) by 12.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,105 shares of the medical research company’s stock after buying an additional 2,706 shares during the quarter. Truist Financial Corp’s holdings in Labcorp were worth $6,298,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG grew its holdings in Labcorp by 2.2% in the 4th quarter. UBS Group AG now owns 495,535 shares of the medical research company’s stock valued at $124,320,000 after buying an additional 10,706 shares in the last quarter. Dakota Wealth Management grew its holdings in Labcorp by 98.6% in the 3rd quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company’s stock valued at $2,958,000 after buying an additional 5,116 shares in the last quarter. Independent Advisor Alliance grew its holdings in shares of Labcorp by 166.6% during the 3rd quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company’s stock worth $3,477,000 after purchasing an additional 7,568 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Labcorp by 12.0% during the 3rd quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company’s stock worth $12,859,000 after purchasing an additional 4,800 shares in the last quarter. Finally, 8 Knots Management LLC grew its holdings in shares of Labcorp by 96.6% during the 3rd quarter. 8 Knots Management LLC now owns 204,859 shares of the medical research company’s stock worth $58,807,000 after purchasing an additional 100,675 shares in the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Stock Performance

NYSE:LH opened at $253.99 on Friday. The stock’s 50-day simple moving average is $269.03 and its 200 day simple moving average is $266.77. The firm has a market capitalization of $20.83 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.78 and a beta of 0.91. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a twelve month low of $239.67 and a twelve month high of $293.72.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 17.99 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LH. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Piper Sandler increased their target price on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. increased their target price on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Insiders Place Their Bets

In related news, EVP Brian J. Caveney sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the sale, the executive vice president directly owned 30,107 shares of the company’s stock, valued at $8,619,935.17. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the transaction, the executive vice president owned 2,579 shares of the company’s stock, valued at $734,782.89. This represents a 17.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is owned by corporate insiders.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.